A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial

References

• Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, Mcpherson R, Francis GA, et al. 2013. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29:151–167
   PubMed Web of Science ®Google Scholar
• Appelkvist EL, Edlund C, Low P, Schedin S, Kalen A, Dallner G. 1993. Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. Clin Investig 71:S97–S102
   Google Scholar
• Barrat E, Zair Y, Sirvent P, Chauveau P, Maudet C, Housez B, Derbord E, et al. 2013. Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. Eur J Nutr [Epub ahead of print]. DOI: 10.1007/s00394-012-0486-2
   PubMedGoogle Scholar
• Baumgartner S, Mensink RP, Plat J. 2011. Plant sterols and stanols in the treatment of dyslipidemia: new insights into targets and mechanisms related to cardiovascular risk. Curr Pharm Des 17:922–932
   PubMed Web of Science ®Google Scholar
• Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. 2006. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295:2262–2269
   PubMed Web of Science ®Google Scholar
• Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. 2005. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25:171–183
   PubMed Web of Science ®Google Scholar
• , Cholesterol Treatment Trialists’ (CTT) CollaboratersMihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590
   PubMedGoogle Scholar
• Dulin MF, Hatcher LF, Sasser HC, Barringer TA. 2006. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 84:1543–1548
   PubMed Web of Science ®Google Scholar
• Egan A, Colman E. 2011. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 365:285–287
   PubMed Web of Science ®Google Scholar
• Endo A. 1979. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot 32:852–854
   PubMed Web of Science ®Google Scholar
• FDA. 2000. Food labeling: health claims; plant sterol/stanol esters and coronary heart disease. Food and Drug Administration, HHS. Interim final rule. Fed Regist 65:54686–54739
   PubMedGoogle Scholar
• FDA. 2003. FDA Approved Summary of Qualified Health Claim on Nuts. Qualified Claims About Cardiovascular Disease Risk. Nuts & Heart Disease. [Docket No. 02P-0505, 07/14/2003]
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
   PubMed Web of Science ®Google Scholar
• Gauthier AP, Lariviere M, Young N. 2009. Psychometric properties of the IPAQ: a validation study in a sample of northern Franco-Ontarians. J Phys Act Health 6:S54–S60
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK. 2002. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356–365
   PubMed Web of Science ®Google Scholar
• Greyling A, De Witt C, Oosthuizen W, Jerling JC. 2006. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 95:968–975
   PubMed Web of Science ®Google Scholar
• Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. 2001. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7:133–139
   PubMed Web of Science ®Google Scholar
• Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. 1999. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231–236
   PubMed Web of Science ®Google Scholar
• Hu FB, Willett WC. 2002. Optimal diets for prevention of coronary heart disease. JAMA 288:2569–2578
   PubMed Web of Science ®Google Scholar
• Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. 2007. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 14:438–440
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Jones PJ, Lamarche B, Kendall CW, Faulkner D, Cermakova L, Gigleux I, et al. 2011. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA 306:831–839
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, De Souza R, Emam A, et al. 2003. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290:502–510
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Kendall CW, Vuksan V, Vidgen E, Parker T, Faulkner D, Mehling CC, et al. 2002. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr 75:834–839
   PubMed Web of Science ®Google Scholar
• Jenkins DJ, Mirrahimi A, Srichaikul K, Berryman CE, Wang L, Carleton A, Abdulnour S, et al. 2010. Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms. J Nutr 140:2302S–2311S
   PubMed Web of Science ®Google Scholar
• Klimek M, Wang S, Ogunkanmi A. 2009. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P & T 34:313–327
   PubMedGoogle Scholar
• Liu CS, Lii CK, Chang LL, Kuo CL, Cheng WL, Su SL, Tsai CW, Chen HW. 2010. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients. Nutr Res 30:118–124
   PubMedGoogle Scholar
• Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. 2006. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4
   PubMedGoogle Scholar
• Mente A, De Koning L, Shannon HS, Anand SS. 2009. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 169:659–669
   PubMed Web of Science ®Google Scholar
• Mills S, Bone K, editors. 1999. Principles and practice of phytotherapy. Edinburgh: Churchill Livingstone
   Google Scholar
• Ogier N, Amiot MJ, George S, Maillot M, Mallmann C, Maraninchi M, Morange S, et al. 2013. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr 52:547–557
   PubMed Web of Science ®Google Scholar
• Palomaki A, Malminiemi K, Solakivi T, Malminiemi O. 1998. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 39:1430–1437
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, et al. 2011. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Galli C, Anderson JW, Arnoldi A. 2009. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 203:8–17
   PubMed Web of Science ®Google Scholar
• Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, Mercier J. 2012. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 259:263–268
   PubMed Web of Science ®Google Scholar
• Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, et al. 2011. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458–2473
   PubMed Web of Science ®Google Scholar
• Stocker R, Bowry VW, Frei B. 1991. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA 88:1646–1650
   PubMed Web of Science ®Google Scholar
• Warnick GR, Wood PD. 1995. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 41:1427–1433
   PubMed Web of Science ®Google Scholar
• Wider B, Pittler MH, Thompson-Coon J, Ernst E. 2013. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev 3:CD003335. doi:10.1002/14651858.CD003335.pub3
   Google Scholar
• Yamashita S, Yamamoto Y. 1997. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 250:66–73
   PubMed Web of Science ®Google Scholar
• Yang HT, Lin SH, Huang SY, Chou HJ. 2005. Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice. Br J Nutr 93:131–135
   PubMedGoogle Scholar
• Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL. 2004. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 110:915–920
   PubMed Web of Science ®Google Scholar